HUTCHMED (China) Limited (HK:0013) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HUTCHMED and Innovent Biologics have received conditional approval from China’s NMPA for the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab) for treating advanced endometrial cancer. This marks a first for fruquintinib combined with an immune checkpoint inhibitor, potentially offering new hope for patients with limited traditional therapy options. The approval is based on promising trial results demonstrating significant efficacy and manageable safety.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Stay Away,’ Says Hans Mosesmann About Intel Stock
- Canaccord Pounds the Table on Archer Aviation Stock
- ‘Don’t Let the Law of Large Numbers Scare You,’ Says Top Investor About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
